The Sleep Apnea drugs in development market research report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sleep Apnea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued products.
GlobalData tracks 32 drugs in development for Sleep Apnea by 21 companies/universities/institutes. The top development phase for Sleep Apnea is phase ii with 16 drugs in that stage. The Sleep Apnea pipeline has 26 drugs in development by companies and six by universities/ institutes. Some of the companies in the Sleep Apnea pipeline products market are: Shionogi-Apnimed Sleep Science, Brigham and Women’s Hospital and Apnimed.
The key targets in the Sleep Apnea pipeline products market include Sodium Dependent Noradrenaline Transporter, Orexin Receptor Type 2, and Orexin/Hypocretin Receptor Type 1.
The key mechanisms of action in the Sleep Apnea pipeline product include Sodium Dependent Noradrenaline Transporter Inhibitor with five drugs in Phase III. The Sleep Apnea pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Sleep Apnea pipeline products market including Small Molecule, and Synthetic Peptide.
Sleep Apnea overview
Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain’s failure to send necessary signals for breathing. Health conditions affecting the brain’s control over airway and chest muscles contribute to this type. Diagnosis involves a sleep study, with treatments including continuous positive air pressure (CPAP) machines and lifestyle adjustments. Surgical intervention may be considered if initial treatments prove ineffective. Untreated sleep apnea can lead to cognitive difficulties and serious health issues.
For a complete picture of Sleep Apnea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
